

Using UPLC-MS/MS for Workplace Drug Testing

Rob Lee¹, Simone Donzelli², Giulia Riccardino³, Luca Salvaderi³, Michela De Francheschi⁴, and Michelle Wood¹

¹Waters Corporation, Wilmslow, UK, ²Waters SPA, Milan, Italy, ³CEDAM Italia, Bresso, Italy, and

⁴Bianalisi Analisi Mediche, Carate Brianza, Italy

GOAL

To develop a UPLC®-MS/MS method for the analysis of 21 substances, commonly measured in workplace drug testing (WPDT) schemes, using a simple dilution of the urine prior to analysis.

BACKGROUND

In recent years WPDT laws have been implemented in certain geographies for workers employed in specific industry sectors, particularly those in safety-critical job roles such as transportation (pilots, train/bus drivers), nuclear–safety employees and construction. Random drug testing in the workplace is aimed, not only at reducing costs in terms of lost productivity and absenteeism, but also at ensuring safety for the individual and the wider community¹.

After prior notification workers provide a urine sample which is commonly screened for a variety of drugs including; opiates, methadone, buprenorphine, cocaine, amphetamines, and cannabinoids by a technique such as immunoassay. Any samples containing analytes above a pre-defined cut-off level (putative positives) are then confirmed by a different technique, often GC-MS or LC-MS/MS.

A simple sensitive UPLC-MS/MS method for substances commonly measured in workplace drug testing schemes.

For some analytes immunoassay is not sufficiently specific and can only indicate the presence of a certain class of compounds rather than pinpoint the actual compound present. In contrast, the use of UPLC-MS/MS for screening can provide a specific, semi-quantitative tool for determining the samples that are positive and improves overall efficiency of the testing process by reducing the number of false positives sent for confirmation.

THE SOLUTION

Combining the ACQUITY UPLC® I-Class System with the Xevo® TQD allows these compounds to be detected at levels lower than the currently applied cut-offs and permits a compound specific semi-quantitative determination of the relevant analytes.

EXPERIMENTAL

Sample preparation

Internal standard (ISTD) mixture (0.05 mL) was added to 0.2 mL urine (either sample or calibrator), which was then vortex-mixed for 5 min at 1200 rpm then centrifuged at 8000 g for 10 min. Supernatant (0.125 mL) was added to 0.375 mL deionized water in a Waters® Maximum Recovery Vial.

Assay concentration of ISTDs was 25 ng/mL.

Chromatography conditions

Column:	ACQUITY UPLC BEH C ₁₈ , 1.7 μm, 2.1 x 100 mm with BEH C ₁₈ 1.7 μm VanGuard™
Column temp.:	40 °C
Sample temp.:	10 °C
Injection volume:	8 μL
Wash solvent:	95% acetonitrile/5% water
Purge solvent:	0.1% formic acid
Flow rate:	400 μL/min
Mobile phase A:	0.1% formic acid
Mobile phase B:	acetonitrile

Gradient

Time (min)	%B	Curve
0	2	Initial
1.5	13	6
1.8	13	6
2.65	36	6
3.00	36	6
3.40	50	6
3.45	95	6
4.75	95	6
4.80	2	6

Mass Spectrometry conditions

MS system:	Xevo TQD
Ionization mode:	ESI with polarity switching
Capillary voltage:	1.0 kV positive, 2.95 kV negative
Source temp.	150°C
Desolvation temp.	500°C
Desolvation gas:	800 L/Hr
Cone gas:	20 L/Hr

Multiple reaction monitoring conditions

Peak #	Compound	RT (min)	Time window (min)	MRM transitions	Cone voltage (V)	Collision energy (eV)	ISTD
1	Normorphine	1.32	1.0–1.80	272.1>201.1 272.1>165.1	50	24 35	Morphine-d6
2	Morphine	1.45	1.0–1.90	286.1>201.1 286.1>153.1	50	24 38	Morphine-d6
3	Norcodeine	2.10	1.90–2.35	286.1>165.1 286.1>153.1	45	40 34	Morphine-d6
5	Dihydrocodeine	2.12	1.95–2.35	302.1>199.0 302.1>171.0	50	39 32	Morphine-d6
6	Codeine	2.17	1.95–2.35	300.1>215.1 300.1>165.0	55	25 38	Morphine-d6
8	6-Monoacetylmorphine (6-MAM)	2.48	2.30–2.70	328.0>165.1 328.0>211.1	52	35 25	Morphine-d6
4	Ephedrine	2.11	1.90–2.30	166.1>117.0 166.1>133.1	25	18 18	Amphetamine-d11
7	Amphetamine	2.39	2.20–2.60	136.0>119.0 136.0>91.0	20	8 12	Amphetamine-d11
9	MDA	2.49	2.30–2.70	180.1>163.0 180.1>133.0	18	8 16	Amphetamine-d11
10	Methamphetamine	2.63	2.45–2.85	150.0>119.0 150.0>91.0	25	10 16	Amphetamine-d11
11	MDMA	2.69	2.50–2.90	194.1>163.0 194.1>105.0	24	11 24	Amphetamine-d11
12	MDEA	2.90	2.70–3.10	208.1>163.0 208.1>72.0	22	12 12	Amphetamine-d11
15	MBDB	3.02	2.85–3.25	208.1>177.1 208.1>135.0	25	11 13	Amphetamine-d11
13	Benzoylcegonine (BZE)	2.95	2.75–3.15	290.1>168.1 290.1>82.0	36	18 28	BZE-d8
14	Ketamine	2.95	2.75–3.15	238.0>207.1 238.0>125.0	28	12 24	BZE-d8
16	Cocaine	3.22	3.05–3.45	304.0>182.1 304.0>82.1	40	18 28	BZE-d8
17	Norbuprenorphine-glucuronide	2.90	2.70–3.10	590.3>414.3 590.3>101.0	70	35 55	Buprenorphine-d4
18	Norbuprenorphine	3.30	3.15–3.55	414.1>101.0 414.2>83.0	55	38 48	Buprenorphine-d4
19	Buprenorphine-glucuronide	3.20	3.00–3.40	644.3>468.2 644.3>101.0	65	40 65	Buprenorphine-d4
20	Buprenorphine	3.61	3.35–3.80	468.2>396.2 468.2>101.0	60	38 42	Buprenorphine-d4
21	EDDP	3.70	3.50–3.95	278.1>249.2 278.1>234.2	50	22 28	Methadone-d9
22	Methadone	3.98	3.80–4.25	310.1>265.2 310.1>105.1	30	16 28	Methadone-d9
23	Carboxy-THC (cTHC)	4.45	4.20–4.80	343.1>299.2 343.1>245.2	45	22 28	cTHC-d3
24	cTHC-glucuronide	4.70	4.20–5.20	519.2>343.2 519.2>299.2	40	22 34	cTHC-d3
	Morphine-d6	1.45	1.00–1.90	292.1>201.1	50	24	
	Amphetamine-d11	2.35	2.25–2.70	147.0>130.0	20	8	
	BZE-d8	2.95	2.75–3.25	298.1>171.1	36	18	
	Buprenorphine-d4	3.60	3.35–3.80	472.2>400.2	60	38	
	Methadone-d9	4.00	3.80–4.25	319.1>268.2	30	16	
	cTHC-d3	4.45	4.20–4.80	346.3>302.2	40	22	

The quantifier transitions are in bold-type.

RESULTS

The acceptance criteria for a positive identification of analytes were the retention time to be within 0.1 min of predicted and the quantifier/qualifier ion ratio to be within 20% of the predicted ratio, which was based on the average of the ratios across the entire calibrator range. Figure 1 shows a chromatogram of a urine calibrator spiked at 25 ng/mL.

To investigate linearity for all analytes, spiked urine calibrators were prepared from 1 ng/mL to 500 ng/mL, except for norbuprenorphine, buprenorphine, their respective glucuronides and cTHC-glucuronide which were from 1 to 250 ng/mL; calibrators were prepared and analysed over five consecutive days.

Peak areas for each MRM trace were generated using the TargetLynx™ Application Manager and referenced to the appropriate ISTD peak area. Semi-quantitative calibration curves were plotted using a 1/x weighting. A quadratic fit was applied to all analytes except the following where a linear fit was applied; normorphine, morphine, norcodeine, cocaine, buprenorphine, EDDP, and methadone. Interday correlation coefficient or coefficient of determination (assessed over five days) was >0.995 for each analyte.

The limit of detection (LOD) was defined as the lowest concentration which gave a signal-to-noise ratio >10:1 (for both transitions) in spiked urine. The lower limit of quantitation (LLOQ) was defined as the lowest concentration which gave a signal to noise ratio >10:1 (for both transitions) and ion ratios within 20% of expected and a %RSD <20% in spiked urine. The LOD and LLOQ for each analyte are summarized in Table 1 along with the assay calibration range.




Figure 1. Chromatogram of a urine calibrator spiked at 25 ng/mL. Peak assignments are listed in Table 1.

Peak #	Compound	LOD spiked urine (ng/mL)	LLOQ spiked urine (ng/mL)	Assay range (ng/mL)
1	Normorphine	2	4	4-500
2	Morphine	2	2	2-500
3	Norcodeine	2	2	2-500
5	Dihydrocodeine	0.25	0.5	2-500
6	Codeine	0.25	2	2-500
8	6-MAM	0.5	2	2-500
4	Ephedrine	0.25	1	1-500
7	Amphetamine	0.5	0.5	1-500
9	MDA	1	1	1-500
10	Methamphetamine	0.25	0.5	1-500
11	MDMA	1	1	1-500
12	MDEA	0.25	0.5	1-500
15	MBDB	0.25	0.25	1-500
13	BZE	0.5	0.5	1-500
14	Ketamine	0.25	0.5	1-500
16	Cocaine	0.25	0.25	1-500
17	Norbuprenorphine-glucuronide	2	5	5-250
18	Norbuprenorphine	1	1	1-250
19	Buprenorphine-glucuronide	2	2	2-250
20	Buprenorphine	0.5	2	2-250
21	EDDP	0.25	0.25	1-500
22	Methadone	0.25	0.25	1-500
23	cTHC	2	4	4-500
24	cTHC-glucuronide	4	5	5-250

Table 1. Calibration range, LODs, and LLOQs (ng/mL) based on the urine dilution protocol.

Matrix effects were investigated at the following concentrations: 10 ng/mL (low), 50 ng/mL (medium) and 250 ng/mL (high), except for norbuprenorphine, buprenorphine, their respective glucuronides and cTHC-glucuronide which were determined at 5 ng/mL (low), 25 ng/mL (medium) and 125 ng/mL (high). The results showed the matrix effect to be less than 20% for the majority of analytes.

Interday accuracy and precision were assessed by analysing three quality control (QC) concentrations (15, 150 and 300 ng/mL, except for norbuprenorphine, buprenorphine, their respective glucuronides and cTHC-glucuronide which were determined at 7.5, 75, and 150 ng/mL) over five different days. The mean achieved values for the quality control replicates over the five day period at the three concentration levels were within 15% of target and the % RSD was <15%.

Analysis of authentic urine samples

Two commercial quality control reference urines and 114 authentic urine samples were analyzed using the described UPLC-MS/MS method.

The method detected and correctly assigned the analytes in both commercial reference urines. The semi-quantitative results obtained using this UPLC-MS/MS method for the analysis of the Bio-Rad Liquichek™ level C2 reference urine were in accordance with the manufactured stated reference values (Figures 2 and 3).




Figure 2. Chromatogram of Bio-Rad Liquichek level C2 reference urine (peaks are scaled to maximum response). Peak assignments are listed in Table 1.




Figure 3. Comparison between the semi-quantitative UPLC-MS/MS analysis of Bio-Rad Liquichek level C2 reference urine and GC analysis.

The authentic samples comprised anonymised samples that had previously been screened using either the Beckman Olympus AU400 or the Abbott Architect 4000 immunoassay system. Any sample that had screened positive by either immunoassay technique had been sent for subsequent confirmation by GC-MS. Eleven of these samples gave putative positives for buprenorphine, methadone, amphetamines and cTHC, but were not confirmed by the subsequent GC-MS assays; all of these samples were negative by the UPLC-MS/MS based screen. Sixty samples were shown to contain at least one and, in some instances, multiple analytes; this was in agreement with the GC-MS confirmation data. Some additional analytes were found that had not been confirmed by the various GC-MS assays as their concentration was below the applied immunoassay cut-offs (opiates 300 ng/mL, amphetamines 500 ng/mL, BZE 300 ng/mL, methadone 500 ng/mL, buprenorphine 5 ng/mL and cannabinoids 50 ng/mL). Figure 4 shows the chromatogram of a sample that screened positive for cTHC yet negative for BZE. In this sample set BZE was the most commonly detected analyte by this UPLC-MS/MS method and was detected in 25 of the 114 samples.




Figure 4. Chromatogram of a sample that screened positive for cTHC yet negative for BZE by immunoassay but by UPLC-MS/MS was shown to contain BZE at 50 ng/mL (lower than the 300 ng/mL cut-off). A negative sample is shown for comparison (upper traces). The traces show the quantifier ions for both analytes only (ISTDs not shown).

SUMMARY

The rise of workplace drug testing has highlighted the need for a quick, accurate, reliable and robust method to initially screen the large number of samples. The developed approach meets these requirements and demonstrates excellent correlation with GC-MS methods.

The use of the ACQUITY UPLC® I-Class system allows for a quick and robust analytical method that can detect all the analytes in a single run, with an injection to injection time of 7 min combined with the simple sample dilution used allows for high sample throughput. Furthermore the superior sensitivity of the Xevo TQD permits detection of the analytes from a simple dilution of the sample at levels lower than the currently applied cut-offs and minimizes false positives.

Acknowledgements

CEDAM Italia, Bresso, Italy and Bianalisi Analisi Mediche, Carate Brianza, Italy for supplying the anonymised authentic urine samples.

References

1. Kazanga I *et al.* Prevalence of drug abuse among workers: Strengths and pitfalls of the recent Italian workplace Drug Testing (WPDT) legislation. *Forensic Science International*. 2012; 215 (1-3): 46–50.

Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

Waters, UPLC, ACQUITY UPLC, Xevo, The Science of What's Possible are registered trademarks of Waters Corporation. VanGuard and TargetLynx are trademarks of Waters Corporation. All other trademarks are the property of their respective owners

©2014 Waters Corporation. Produced in the U.S.A. June 2014 720005032EN AO-PDF

Waters Corporation
34 Maple Street
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990
www.waters.com